Dr. Flynn on Obinutuzumab for the Treatment of CLL

(1:11)

Obinutuzumab for Indolent Lymphoma

(5:24)

CLL14: Venetoclax plus obinutuzumab for CLL

(5:54)

Venetoclax Combined with Obinutuzumab for Untreated CLL (Chronic Lymphocytic Leukemia)

(8:57)

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL

(1:43)

New Data Supports Long Term Efficacy of Venetoclax-Obinutuzumab for CLL Patients

(8:46)

The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results

(2:6)

Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL

(53)

Acalabrutinib and Venetoclax VS. Venetoclax and Obinutuzumab for CLL - Dr. Matt Davids

(6:20)

Atezolizumab combined with venetoclax and obinutuzumab for frontline CLL

(1:21)

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

(1:2)

Obinutuzumab increases survival in CLL patients with comorbidities

(2:4)

Deciding on Rituximab Versus Obinutuzumab in Follicular Lymphoma

(1:32)

Debate: Is obinutuzumab superior to rituximab in lymphoma? - No

(14:2)

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

(1:1econd)

Is obinutuzumab our key to improving the treatment of FL?

(2:46)

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL

(1:46)

Dr. Valentin Goede on Obinutuzumab Versus Rituximab in CLL

(1:43)

Rituximab, Obinutuzumab, and Ofatumumab in CLL

(4:7)

Richard Furie, MD: Obinutuzumab for Lupus Nephritis

(1:9)